The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.